Blue Owl Capital led a $150m Series B round in Latigo Biotherapeutics.

Blue Owl Capital, an investment firm, led a $150m Series B round in Latigo Biotherapeutics, a biotechnology research company, with participation from Deep Track Capital, Access Biotechnology, Qatar Investment Authority and Sanofi Ventures. “The need for non-opioid pain treatments has never been more urgent, and this financing allows us to accelerate the development of our robust portfolio of pain medicines that have the potential to transform the treatment landscape,” Nima Farzan, Latigo CEO.